

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Paris et al.	Confirmation No.:	7571
Serial No.:	10/780,905	Art Unit:	1654
Filed:	February 18, 2004	Examiner:	Cordero Garcia, Marcela M.
For:	ANTI-ANGIOGENIC AND ANTI-TUMORAL PROPERTIES OF BETA AND GAMMA SECRETASE INHIBITORS	Attorney Docket No.:	12062-105006 (RSK006)

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56 AND § 1.97

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim in the application, Attorneys for Applicants hereby invite the Examiner's attention to the references **B01** and **C17-C20**, which are listed on the attached List of References Cited by Applicant. Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), a copy of references **B01** and **C17-C20** are provided herewith.


Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b)(4), since this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits after the filing of a request for continued examination, it is believed that no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to King & Spalding Deposit Account No. 50-3732.

Respectfully submitted,

Date: October 23, 2007


Richard M. Enmon, Jr.

52,865

(Reg. No.)

KING & SPALDING

1185 Avenue of the Americas
New York, New York 10036
(212) 556-2100